… Clinical benefit on ARR was independent of exposure, but greater risk reduction in … ocrelizumab
exposure in patients with RMS and PPMS, suggesting that higher ocrelizumab exposure …

… A plausible explanation for this observation could be that higher ocrelizumab exposure in
lighter patients leads to more complete B-cell depletion and to a more pronounced delay in …

… The aim of this analysis was to characterize the PK of ocrelizumab, to identify covariates
influencing drug exposure, and to compute individual patient exposure metrics to allow for the …

… exposure were associated with an increased risk of MRI activity during ocrelizumab treatment,
with previous DMT exposure … Accordingly, a previous DMT exposure was associated with …

… Our results show that in patients with MS exposed to OCR for 12 months, mean T-cell values,
including CD3 + , CD4 + , and CD8 + cells, are not reduced overall. Nevertheless, when …

… For all malignancies, cases of nonmelanoma skin cancer (NMSC) were excluded from
the ocrelizumab (OCR) all-exposure population and from the Danish MS registry to allow a …

… in the overall OCR exposure population for the pooled OPERA studies. The crude incidence
rate of all malignancies per 100 patient-years in the overall OCR exposure population was …

… , if an active drug (ie another approved DMD for MS) and placebo were used as comparators
to the same ocrelizumab exposed group of patients in the same study, only one comparator …

… that enrolled patients with relapsing MS (RMS). Patients in the ocrelizumab group initially …
Ocrelizumab-treated patients also received subcutaneous (SC) placebo injections 3 times …

… with a baseline EDSS score ≥ 2); annualized rate of PDRs at Week 96 (ARR; calculated as
the total number of PDRs for all patients divided by the total patient-years of exposure to that …